OakChart

Kura Oncology Inc

KURAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

7.73+0.16 (2.11%)
2026-11-11 22:34 CET
Market cap
673.43 USD m
Revenue, TTM
79.31 USD m
Net income, TTM
-292.87 USD m
Free cash flow, TTM
-89.12 USD m
EPS diluted, TTM
-3.30
P/E
-
Compare

Price

KURA against its 20, 50 and 200-day averages
2050200beatearnings
8.0010.0012.0014.004.1M8.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KURAclose 7.7320-day 9.1450-day 10.39200-day 9.787.7352w high52w low

44.4% under the 52-week high of 13.90 on 25 Aug 2026. 52-week low 6.75 on 6 Nov 2026. Last 15 sessions, 62.3% high to low

Volume 1.74× normal · the line is the 50-bar volume average

Profile

KURA
52-week range, 14% of the way up
6.7513.90

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

IndexRUT
Employees260
IPOSep 16, 2015
Beta0.57
ATR, 14d0.69
Rel volume1.74
Short float14.62%
Insider own2.78%
Inst own101.09%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap687.66M
Enterprise Value221.39M
Income-292.87M
Sales79.31M
Book/sh0.20
Cash/sh5.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees260
IPOSep 16, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S8.67
P/B39.54
P/C1.40
P/FCF-
EV/EBITDA-
EV/Sales2.79
Quick Ratio3.56
Current Ratio3.60
Debt/Eq1.44
LT Debt/Eq0.86
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.30
EPS next Y-2.41
EPS next Q-0.82
EPS this Y-1.96%
EPS next Y25.54%
EPS next 5Y16.32%
EPS past 3/5Y-16.16% -13.48%
Sales past 3/5Y- -
EPS Y/Y TTM-48.89%
Sales Y/Y TTM-23.76%
EPS Q/Q7.54%
Sales Q/Q10.07%
EarningsNov 10 AMC
EPS/Sales Surpr.4.84% -8.44%

Ownership

Insider Own2.78%
Insider Trans-2.12%
Inst Own101.09%
Inst Trans-1.66%
ROA-48.17%
ROE-224.85%
ROIC-877.39%
Gross Margin97.40%
Oper. Margin-394.32%
Profit Margin-369.26%
SMA20-15.40%
SMA50-25.61%
SMA200-20.96%
Trades-

Technical

Shs Outstand91.87M
Shs Float86.49M
Short Float14.62%
Short Ratio6.01
Short Interest12.64M
52W High13.90 -44.39%
52W Low6.75 14.52%
Volatility15.59% 7.86%
ATR (14)0.69
RSI (14)34.71
Beta0.57
Rel Volume1.74
Avg Volume2.10M
Volume3,651,105

Performance

Perf Week1.58%
Perf Month-21.36%
Perf Quarter-23.39%
Perf Half Y-18.46%
Perf YTD-25.60%
Perf Year-27.69%
Perf 3Y-9.27%
Perf 5Y-55.85%
Perf 10Y48.66%
Recom1.19
Target Price31.85
Prev Close7.57
Price7.73
Change %2.11%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 01, 2026InitiatedJJP MorganOverweight$30+288.1%
Apr 14, 2026InitiatedLLake StreetBuy$23+197.5%
Sep 04, 2025InitiatedGGuggenheimNeutral
Feb 06, 2025DowngradeBBTIG ResearchBuy → Neutral
Oct 24, 2024InitiatedUUBSBuy$27+249.3%
Oct 14, 2024DowngradeSStifelBuy → Hold$26 → $19+145.8%
Dec 22, 2023InitiatedMMizuhoBuy$26+236.4%
Aug 11, 2023InitiatedBBofA SecuritiesBuy$31+301.0%
Jul 27, 2023InitiatedBScotiabankSector Perform$10.50+35.8%
May 17, 2023InitiatedBBTIG ResearchBuy$31+301.0%

Peers

Mkt cap
TickerCompanyMkt cap
SNDXSyndax Pharmaceuticals Inc863.37M
RIGLRigel Pharmaceuticals838.31M
DMRADamora Therapeutics Inc1.44B
AAPGAscentage Pharma Group International ADR1.40B
GERNGeron Corp657.13M
SLSSELLAS Life Sciences Group Inc1.70B
INCYIncyte Corp24.92B
EXELExelixis Inc17.25B
ABBVAbbvie Inc521.41B
ATNMActinium Pharmaceuticals Inc49.99M

Insider trading

latest 14 of 66
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bair Teresa BrophyChief Legal OfficerSep 28 '26Sale10.508,44288,618187,002Sep 29 06:30 PM
FORD KATHLEENChief Operating OfficerSep 28 '26Sale10.506,90672,494146,654Sep 29 06:30 PM
FORD KATHLEENChief Operating OfficerSep 29 '26Sale10.753,66839,437142,986Sep 29 06:30 PM
Leoni MollieChief Medical OfficerSep 29 '26Sale10.7528,802309,567141,095Sep 29 06:30 PM
Leoni MollieChief Medical OfficerSep 28 '26Sale10.5012,448130,670169,897Sep 29 06:30 PM
DOYLE THOMAS JAMESSVP, Finance & AccountingSep 28 '26Sale10.504,60748,361142,428Sep 29 06:30 PM
Powl Brian T.Chief Commercial OfficerSep 28 '26Sale10.5317,020179,183152,249Sep 29 06:30 PM
Powl Brian T.Chief Commercial OfficerSep 29 '26Sale10.7515,430165,852136,819Sep 29 06:30 PM
BRIAN POWLOfficerSep 29 '26Proposed Sale10.6115,430163,712Sep 29 04:25 PM
MOLLIE LEONIOfficerSep 29 '26Proposed Sale10.6128,802305,589Sep 29 04:25 PM
KATHLEEN FORDOfficerSep 29 '26Proposed Sale10.613,66838,917Sep 29 04:25 PM
POWL BRIAN TOfficerSep 28 '26Proposed Sale10.769,02097,055Sep 28 09:00 PM
LEONI MOLLIEOfficerSep 28 '26Proposed Sale10.7612,448133,940Sep 28 08:00 PM
BAIR TERESA BROPHYOfficerSep 28 '26Proposed Sale10.768,44290,836Sep 28 08:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • Kura Oncology Narrows Loss And Beats As KOMZIFTI Launch Builds, But Collaboration Cut, Dilution, And Debt Shape A Battered Stock's Setup (Earnings Whispers)
  • Kura Oncology: Q3 Earnings Snapshot (Associated Press)
  • Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
  • Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.91%
  • Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026 (GlobeNewswire) -22.98%
  • Kura Oncology's Third Quarter Tests Whether ComSifty's Launch Momentum Is Built To Last (Earnings Whispers)
  • Kura Oncology to Report Third Quarter Financial Results on November 10 (GlobeNewswire)
  • Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes (GlobeNewswire) -5.44%
  • Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes (GlobeNewswire)
  • Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Caspian Therapeutics and Kura Oncology Report Preclinical Data for Diabetes Candidate KO-7246 (InvestorsHub)
  • Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes (GlobeNewswire)
  • Kura spins diabetes work into a Lilly-backed biotech startup (BioPharma Dive)
  • Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.780-0.820-0.78222.8424.9414
2026Q22026-08-12-0.770-0.877-0.76920.8720.1613
2026Q12026-05-12-0.830-0.835-0.82818.2725.9713
2025Q42026-03-05-0.920-0.639-0.92017.3435.4312
2025Q32025-11-04-0.850-0.730-0.84620.7518.9411
2025Q22025-08-07-0.750-0.366-0.75515.2942.6710
2025Q12025-05-01-0.660-0.600-0.65714.1117.5311
2024Q42025-02-26-0.220-0.636-0.22153.8853.8210
2024Q32024-11-07-0.630-0.626-0.6260.000.0014
2024Q22024-08-08-0.590-0.626-0.5870.000.0013
2024Q12024-05-02-0.590-0.547-0.5900.000.0014
2023Q42024-02-27-0.550-0.551-0.5530.000.0013
2023Q32023-11-02-0.500-0.540-0.5000.000.0013
2023Q22023-08-03-0.530-0.544-0.5330.000.0012
2023Q12023-05-10-0.500-0.538-0.4980.000.0010
2022Q42023-02-23-0.490-0.572-0.4890.000.0010

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.510-1.528-1.5050.000.00
2020FY-1.690-1.695-1.6890.000.00
2021FY-1.970-2.022-1.9660.000.00
2022FY-2.030-2.139-2.0280.000.00
2023FY-2.080-2.080-2.0840.000.00
2024FY-2.020-2.450-2.01953.8850.23
2025FY-3.180-2.869-3.18067.4885.37
2026FY--3.242--90.39
2027FY--2.414--186.02
2028FY--1.864--250.24
2029FY--0.331--358.59
2030FY-1.909--551.99

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-11144527.9421.9732.44
2026Q4S2026-11-10142229.2521.9737.03
2026Q4S2026-10-30142229.2521.9737.03
2026Q4S2026-10-28142129.3021.9737.67
2026Q4S2026-10-27142129.1820.2837.67
2026Q4S2026-10-19147329.1820.2837.67
2026Q4S2026-10-13146328.9620.2837.67
2026Q4S2026-09-30146328.9620.2837.67
2026Q4S2026-08-28136329.1120.2837.67
2026Q4S2026-08-21136229.6020.2837.67
2026Q4S2026-08-20136229.6020.2837.67
2026Q4S2026-08-13135229.4918.8737.67
2026Q4S2026-08-02132027.7018.8734.36
2026Q4S2026-07-27132127.7018.8734.36

Estimate history

EPS, annual-1.52-1.718-1.505-1.689-1.966-2.028-2.084-2.019-3.178-3.2982
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.626-0.221-0.657-0.755-0.846-0.92-0.828-0.769-0.782
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000053.88367.48279.31
Period201720182019202020212022202320242025TTM
Sales, quarterly053.88314.10815.28820.7517.33618.26520.87422.839
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual29.42438.14845.38466.19466.57268.31474.3578.22987.85591.873
Period201720182019202020212022202320242025MRQ
Shares, quarterly77.74978.22980.77886.79787.01687.85588.76388.95491.873
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue79.3167.4853.880.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.061.090.850.850.760.560.190.000.01
Gross Profit77.2566.3953.03-0.85-0.76-0.56-0.190.00-0.01
Selling, General and Administrative Excl. Other390.00370.02246.23164.96139.11130.7091.7067.4862.87
Research and Development258.44251.07169.97115.2392.8184.7260.4047.8346.79
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-312.75-303.63-193.19-165.80-139.87-131.26-91.90-67.48-62.88
Interest Expense1.381.511.621.550.230.200.580.580.97
Unusual Expense-30.590.000.000.000.000.210.000.000.50
Net Income Before Taxes-292.79-278.37-171.97-152.63-135.84-130.47-89.62-63.14-60.45
Income Taxes0.080.302.020.000.000.000.000.000.00
Consolidated Net Income-292.87-278.67-173.98-152.63-135.84-130.47-89.62-63.14-60.45
Net Income From Continuing Operations-292.87-278.67-173.98-152.63-135.84-130.47-89.62-63.14-60.45
Net Income-292.87-278.67-173.98-152.63-135.84-130.47-89.62-63.14-60.45
EPS (Recurring)-3.50-3.18-2.02-2.08-2.03-1.96-1.69-1.51-1.71
EPS (Basic, Before Extraordinaries)-3.30-3.18-2.02-2.08-2.03-1.97-1.69-1.51-1.72
EPS (Diluted)-3.30-3.18-2.02-2.08-2.03-1.97-1.69-1.51-1.72
EBITDA-311.30-302.60-192.35-164.96-139.11-130.70-91.70-67.48-62.87
Non-Operating Income (Expense)-9.2526.7722.8514.724.251.212.854.923.90
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense30.2729.3226.7828.0826.3223.5812.819.418.65
Price To Sales Ratio12.1313.5013.93------
Gross Margin97.4098.3998.43------
Operating Margin-394.32-449.94-358.55------
Net Margin-369.26-412.95-322.89------
Shares Outstanding91.8787.8678.2374.3568.3166.5766.1945.3838.15
Market Capitalization673.43673.43677.321,068.03847.15931.782,116.96623.08534.04

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue22.8420.8718.2717.3420.7515.2914.1153.88
Cost of Goods Sold Incl. D&A0.370.610.620.460.160.220.240.20
Gross Profit22.4720.2617.6516.8820.5915.0613.8753.68
Selling, General and Administrative Excl. Other97.1393.2796.46103.14100.5887.7378.5776.13
Research and Development66.8861.8965.2664.4167.9162.7855.9752.27
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-74.66-73.01-78.81-86.27-80.00-72.67-64.70-22.45
Interest Expense0.350.340.340.350.390.390.380.40
Unusual Expense-30.590.000.000.000.000.000.000.00
Net Income Before Taxes-70.22-68.32-73.33-80.93-74.12-66.12-57.20-17.20
Income Taxes0.000.010.010.070.000.000.232.02
Consolidated Net Income-70.22-68.33-73.33-81.00-74.12-66.12-57.43-19.22
Net Income From Continuing Operations-70.22-68.33-73.33-81.00-74.12-66.12-57.43-19.22
Net Income-70.22-68.33-73.33-81.00-74.12-66.12-57.43-19.22
EPS (Recurring)-1.02-0.77-0.83-0.92-0.85-0.75-0.66-0.22
EPS (Basic, Before Extraordinaries)-0.78-0.77-0.83-0.92-0.85-0.75-0.66-0.22
EPS (Diluted)-0.78-0.77-0.83-0.92-0.85-0.75-0.66-0.22
EBITDA-74.33-72.64-78.46-85.86-79.83-72.44-64.46-22.25
Non-Operating Income (Expense)-25.795.035.835.696.276.937.885.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.176.496.658.978.666.956.206.82
Price To Sales Ratio12.1312.6210.0613.567.466.078.4914.09
Gross Margin98.3897.0796.6297.3599.2198.5398.2999.62
Operating Margin-326.89-349.77-431.51-497.62-385.53-475.31-458.61-41.67
Net Margin-307.43-327.33-401.49-467.23-357.19-432.51-407.07-35.66
Shares Outstanding91.8788.9588.7687.8687.0286.8080.7878.23
Market Capitalization673.43973.86718.12904.11768.16499.54532.98677.32

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments667.24727.39423.96437.99517.96633.32236.89178.9993.14
Short Term Receivables12.606.102.800.000.000.000.030.220.22
Inventories0.410.000.000.000.000.000.000.000.00
Other Current Assets28.4111.335.728.444.333.972.681.991.28
Total Current Assets708.66744.83432.48446.43522.29637.29239.60181.2094.64
Net Property, Plant & Equipment15.167.498.856.388.258.360.280.000.01
Total Investments and Advances0.000.000.200.210.210.210.000.000.00
Deferred Tax Assets-280.52-------
Other Assets14.547.847.403.293.311.352.091.181.20
Total Assets738.361,040.67448.94456.31534.05647.21241.97182.3895.85
Short Term Debt Incl. Current Port. of LT Debt1.284.491.512.322.265.090.500.001.53
Accounts Payable5.021.472.301.533.242.753.534.121.46
Income Tax Payable0.242.06-------
Other Current Liabilities110.4470.6931.4620.2116.9618.1811.549.497.04
Total Current Liabilities116.9778.7135.2624.0622.4526.0215.5613.6210.03
Long Term Debt19.1812.1115.6911.714.619.897.257.505.57
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-280.52-------
Other Liabilities428.07255.700.700.270.380.400.380.280.39
Total Liabilities564.23627.0351.6636.0327.4436.3123.1921.3915.99
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity174.13413.64397.27420.28506.61610.90218.78160.9979.86
Total Shareholders Equity174.13413.64397.27420.28506.61610.90218.78160.9979.86
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity174.13413.64397.27420.28506.61610.90218.78160.9979.86
Total Liabilities & Stockholders Equity738.361,040.67448.94456.31534.05647.21241.97182.3895.85
Book Value Per Share1.985.295.346.157.619.234.824.222.71
Tangible Book Value Per Share1.985.295.346.157.619.234.824.222.71
Full-Time Employees26019214213312189604332
Price to Book Ratio13.901.602.481.981.843.542.853.335.00
Return on Assets-31.33-23.36-33.72-27.43-22.09-20.16-29.76-43.45-42.78
Return on Equity-94.82-42.91-37.34-29.31-23.35-21.60-33.25-50.19-51.83
Return on Invested Capital-144.15-40.87-36.96-31.45-25.52-14.44-27.93-35.88-41.48
Quick Ratio6.059.4612.2618.5623.2624.4915.3913.319.43
Current Ratio6.069.4612.2618.5623.2624.4915.3913.319.43

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-292.87-278.67-173.98-152.63-135.84-130.47-89.62-63.14-60.45
Depreciation1.461.030.850.850.760.560.190.000.01
Other Funds (Non Cash)32.9229.1421.2819.1428.0028.5813.228.317.40
Funds from Operations-258.49-248.50-151.86-132.64-107.08-101.33-76.21-54.83-53.04
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital172.92184.44286.177.82-2.98-3.226.380.074.38
Cash from Operating Activities-85.57-64.06134.32-124.82-110.06-104.55-69.83-54.76-48.66
Capital Expenditures-3.55-6.64-0.47-0.17-0.63-1.15-2.170.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments16.53-6.46-101.1215.7233.25-125.69-97.77-46.33-79.30
Purchase of Investments-548.47-761.59-659.05-409.82-270.65-445.66-320.96-227.57-237.44
Sale Or Maturity of Investments565.00755.13557.93425.55303.91319.97223.20181.25158.14
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities12.98-13.10-101.5915.5632.63-126.83-99.94-46.33-79.30
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock35.251.79154.4294.7829.144.43469.58111.10133.26
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock35.251.79154.4294.7829.144.43469.58111.10133.26
Proceedsfrom Stock Options31.540.000.0093.5824.720.00459.33108.17132.17
Issuance or Reduction of Debt, Net0.000.000.000.009.43-7.25-0.250.00-0.62
Change in Long Term Debt0.000.000.000.009.43-7.25-0.250.00-0.62
Issuance of Long Term Debt0.000.000.000.009.430.000.000.000.63
Reduction of Long Term Debt0.000.000.000.000.00-7.25-0.250.00-1.25
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.610.000.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.610.000.000.00
Cash from Financing Activities35.251.79154.4294.7838.56-3.44469.33111.10132.64
Net Change in Cash-37.35-75.36187.14-14.48-38.87-234.82299.5710.024.69
Free Cash Flow-89.12-70.70133.84-124.99-110.69-105.70-72.00-54.76-48.66
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--5.61------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments492.10519.02580.82667.24549.66630.73
Short Term Receivables17.5913.0513.6512.6039.248.17
Inventories4.982.480.840.410.000.00
Other Current Assets20.0324.8828.4728.4131.7621.17
Total Current Assets534.70559.44623.78708.66620.66660.08
Net Property, Plant & Equipment14.3714.6214.7815.1614.9411.78
Total Investments and Advances4.300.000.000.000.000.00
Other Assets13.1313.7313.9914.5413.7810.57
Total Assets566.50587.79652.55738.36649.38682.42
Short Term Debt Incl. Current Port. of LT Debt10.415.511.281.285.774.81
Accounts Payable8.132.397.045.024.671.70
Income Tax Payable-0.060.240.240.000.00
Other Current Liabilities130.19110.2392.93110.44110.87100.66
Total Current Liabilities148.73118.19101.50116.97121.30107.17
Long Term Debt15.4218.9522.9919.1813.7014.66
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities384.39402.22420.18428.07271.83255.10
Total Liabilities548.54539.36544.67564.23406.84376.94
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity17.9648.43107.88174.13242.54305.49
Total Shareholders Equity17.9648.43107.88174.13242.54305.49
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity17.9648.43107.88174.13242.54305.49
Total Liabilities & Stockholders Equity566.50587.79652.55738.36649.38682.42
Book Value Per Share0.200.541.221.982.793.52
Tangible Book Value Per Share0.200.541.221.982.793.52
Full-Time Employees---260--
Price to Book Ratio13.909.034.103.732.511.28
Return on Assets-48.17-46.73-42.19-31.33-38.45-32.93
Return on Equity-224.85-167.71-124.74-94.82-65.10-51.11
Return on Invested Capital-210.35-101.41-56.03-41.90-28.92-20.65
Quick Ratio3.564.716.146.055.126.16
Current Ratio3.604.736.156.065.126.16

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-70.22-68.33-73.33-81.00-74.12-66.12
Depreciation0.330.370.350.400.160.22
Other Funds (Non Cash)7.657.587.6210.079.184.57
Funds from Operations-62.23-60.38-65.36-70.52-64.77-61.33
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital7.79-2.17-20.50187.80-15.8632.55
Cash from Operating Activities-54.44-62.55-85.85117.27-80.63-28.78
Capital Expenditures-0.45-0.66-0.13-2.32-2.57-1.46
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments10.0492.86-24.10-62.2796.5360.40
Purchase of Investments-117.46-19.64-171.60-239.78-138.50-114.60
Sale Or Maturity of Investments127.50112.50147.50177.50235.03175.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities9.6092.21-24.23-64.6093.9758.94
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock32.541.500.071.140.000.52
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock32.541.500.071.140.000.52
Proceedsfrom Stock Options31.540.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities32.541.500.071.140.000.52
Net Change in Cash-12.3031.16-110.0253.8113.3430.68
Free Cash Flow-54.89-63.20-85.98114.95-83.19-30.23
Price to Free Cash Flow----9.334.11

Revenue breakdown

Collaboration2024: 53.88M 2025: 65.35M
Product2025: 2.13M
United States2024: 53.88M 2025: 67.48M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.62%12.6M86.5M1.88M
2026-10-1516.56%14.3M86.5M1.79M
2026-09-3016.67%14.4M86.5M1.82M
2026-09-1517.15%14.8M86.4M1.79M
2026-08-3115.53%13.4M86.4M1.84M
2026-08-1415.19%13.1M86.4M1.77M
2026-07-3115.30%13.2M86.0M1.75M
2026-07-1515.97%13.7M86.0M1.79M
2026-06-3017.55%15.1M86.0M1.72M
2026-06-1517.00%14.6M85.9M1.64M
2026-05-2915.82%13.6M85.9M1.60M
2026-05-1518.21%15.6M85.9M1.46M
2026-04-3017.84%15.4M86.5M1.46M
2026-04-1517.52%15.0M85.6M1.47M
2026-03-3116.59%14.2M85.6M1.47M
2026-03-1316.79%14.4M85.6M1.57M
2026-02-2717.03%14.6M85.6M1.50M
2026-02-1316.65%14.0M84.4M1.58M
2026-01-3016.19%13.6M84.2M1.74M
2026-01-1514.63%12.3M84.2M1.85M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.004.509.000.000.0000.000.000.990-0.0140.000
call2.003.508.000.000.0000.000.000.983-0.0150.001
call3.002.507.000.0018.1860.000.000.975-0.0150.001
call4.001.556.000.0012.7760.000.000.966-0.0140.001
call5.000.704.900.009.4110.000.000.952-0.0130.001
call6.000.204.903.8010.4106.000.000.928-0.0120.002
call7.000.002.700.905.20516.000.000.727-0.0290.004
call8.000.000.550.300.85870694.000.477-0.0360.005
call9.000.000.400.051.49470234.000.297-0.0350.004
call10.000.000.100.051.5701,11960.000.205-0.0310.004
call11.000.000.100.051.38056010.000.072-0.0130.002
call12.000.000.350.171.9702040.000.101-0.0240.002
call13.000.000.400.022.2211,0570.000.092-0.0250.002
call14.000.004.300.062.44540.000.000.086-0.0260.002
call15.000.004.300.102.6495640.000.081-0.0270.002
call16.000.004.300.002.8340.000.000.077-0.0280.002
call17.000.001.550.153.0061930.000.074-0.0290.002
call18.000.004.300.053.1643630.000.071-0.0290.002
call19.000.004.300.003.3110.000.000.069-0.0300.002
put1.000.000.050.007.2000.000.00-0.011-0.0130.000
put2.000.000.050.004.7340.000.00-0.018-0.0130.001
put3.000.000.050.003.3790.000.00-0.026-0.0130.001
put4.000.004.300.002.6240.000.00-0.034-0.0140.001
put5.000.001.000.001.8490.000.00-0.048-0.0130.001
put6.000.000.050.182.07220.000.00-0.159-0.0340.003
put7.000.004.400.151.18538.001.00-0.273-0.0290.004
put8.000.001.250.272.29685.001.00-0.523-0.0360.005
put9.000.002.601.323.72727.00272-0.703-0.0340.004
put10.000.403.702.554.4822700.00-0.867-0.0190.003
put11.001.004.803.385.1461150.00-0.887-0.0210.002
put12.002.006.002.545.9552170.00-0.899-0.0220.002
put13.003.007.503.367.34245.000.00-0.908-0.0240.002
put14.004.008.503.787.64711.000.00-0.914-0.0250.002
put15.005.009.500.007.9220.000.00-0.919-0.0250.002
put16.006.0010.500.008.1720.000.00-0.923-0.0260.002
put17.007.0011.500.008.4020.000.00-0.926-0.0270.002
put18.008.0012.500.008.6140.000.00-0.929-0.0270.002
put19.009.0013.500.008.8100.000.00-0.931-0.0280.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-27SCHEDULE 13G/ASEC
2026-09-29144Filing for proposed sale of securities under Rule 144.SEC
2026-09-29144Filing for proposed sale of securities under Rule 144.SEC
2026-09-29144Filing for proposed sale of securities under Rule 144.SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-24144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.26M9
2026-082.35M2449.34K2
2026-070000
2026-0600834.28K1
2026-0500154.77K4
2026-040000
2026-030000
2026-020000
2026-0100305.16K6
2025-1200341.70K2
2025-1100498.68K5

Institutional holders

Manager% owned
BlackRock, Inc.11.84%
MONTANOVA CAPITAL, LLC9.66%
BVF INC/IL9.51%
STATE STREET CORP6.00%
VANGUARD CAPITAL MANAGEMENT LLC4.41%
ARMISTICE CAPITAL, LLC4.14%
AQR CAPITAL MANAGEMENT LLC3.52%
GEODE CAPITAL MANAGEMENT, LLC2.58%
GOLDMAN SACHS GROUP INC2.55%
ALETHEA CAPITAL MANAGEMENT, LLC2.44%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.50%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.15%
iShares Russell 2000 ETF2.49%
VANGUARD EXTENDED MARKET INDEX FUND1.16%
Fidelity Small Cap Index Fund1.05%
iShares Russell 2000 Growth ETF0.88%
iShares Biotechnology ETF0.68%
BlackRock Advantage Small Cap Core Fund0.59%
VANGUARD RUSSELL 2000 INDEX FUND0.55%
Fidelity Extended Market Index Fund0.50%

OakChart. KURA. Cached 15 minutes.